A TROP2-targeting ADC synergizes with oxidative phosphorylation inhibitor to enhance apoptosis in ESCC by suppressing the PI3K-AKT-mTOR signaling pathway.

ABSTRACT: Currently, there are no effective targeted therapies for advanced esophageal squamous cell carcinoma (ESCC). Trophoblast cell surface antigen-2 (TROP2) are considered robust therapeutic targets which leverages antibody-drug conjugates (ADCs) to control solid tumors. Mitochondrial oxidative phosphorylation (OXPHOS) influences the growth of cancer cells, metastasis, and drug resistance. However, whether inhibiting OXPHOS can potentiate the efficacy of TROP2-targeting ADCs is not well understood. Here, we investigated the therapeutic efficacy of IMMU132 (IMMU), an ADC targeting TROP2, either alone or in combination with IACS010759 (IACS), a selective OXPHOS inhibitor, through clinically ESCC models. Immunohistochemical analysis was performed on a cohort of 222 patients, which revealed that 94

SUBMITTER: Liu X 

PROVIDER: S-EPMC12827259 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature